Vancomycin

Novel Study Demonstrates the Hospital-Wide Impact of the Steripath® Initial Specimen Diversion Device® on Blood Culture Contamination Rates and Sepsis Testing Accuracy at WVU Medicine - United Hospital Center

Retrieved on: 
Mercredi, avril 6, 2022
ISDT, Magnolia, Laboratory, Blood culture, Infection, Invention, Nursing, Patent, Clinical, Intravenous therapy, Multimedia, Patient, American Journal, WVU Medicine, Quality, Procedure, University Health System, Hospital, CEO, American Journal of Medical Quality, Emergency, Sepsis, Goal, Vancomycin, Intellectual property, CLSI, Clinical and Laboratory Standards Institute, FDA, MedStar Washington Hospital Center, Collection, Pharmaceutical industry, Medical device

SEATTLE, April 6, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing accuracy,1 today announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System, clinically evaluating the impact of Steripath in reducing false-positive blood culture results throughout the hospital.

Key Points: 
  • The WVU Medicine leadership have prioritized a strategic initiative to reduce blood culture contamination system-wide, which includes an assessment of the impact of Steripath.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.
  • Initial Specimen Diversion Device reduces blood culture contamination and vancomycin use in academic medical center.
  • Getting to zero: impact of a device to reduce blood culture contamination and false-positive central line-associated blood stream infections.

TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST

Retrieved on: 
Jeudi, mars 31, 2022
Drug of last resort, Hospital-acquired pneumonia, MIC, Skin, Rheumatology, NASDAQ, Partnership, Marketing, Gram-positive bacteria, S. aureus, Gastroenterology, Multimedia, Scleroderma, Patient, Adult, Ventilator-associated pneumonia, SEC, Duchenne muscular dystrophy, Subclinical infection, Lists of disasters, CEO, Staphylococcus aureus, View, Skin infection, Health, Structured Product Labeling, Injection, Vancomycin, Granisetron, Physician, Cardiomyopathy, Infection, FDA, MRSA, MSSA, Form 10-Q, Pneumonia, Collection, Pharmaceutical industry, Vaccine, Kingdom, Telavancin

NASHVILLE, Tenn. and RIYADH, Saudi Arabia, March 31, 2022 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), headquartered in Nashville, and Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East, headquartered in Riyadh, Saudi Arabia, today announced the launch of Cumberland's Vibativ® (telavancin) injection in the Middle East. The announcement follows an agreement between the companies providing Tabuk the exclusive rights to register and promote the product for patients in Saudi Arabia, Jordan and potentially other countries in the Middle East.  

Key Points: 
  • As a once-daily dosed antibiotic, Vibativ does not require therapeutic drug monitoring, decreasing health care professionals' exposure to the patient.
  • "Tabuk is a well-respected pharmaceutical company with a strong distribution network throughout the Middle East, and we are proud to partner with them to introduce Vibativ to this market," said A.J.
  • About Tabuk Pharmaceutical Manufacturing Co.
    Tabuk Pharmaceutical Manufacturing Company is a leading Saudi pharmaceutical company with a regional presence in the Middle East and North Africa.
  • Tabuk Pharmaceuticals reaches patients in 17 countries in the Middle East and Africa, in addition to futuristic plans to expand its presence in the region.

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

Retrieved on: 
Vendredi, mars 18, 2022
Biotechnology, Infectious Diseases, Health, Stem Cells, Clinical Trials, Memorial Sloan Kettering Cancer Center, Private Securities Litigation Reform Act, Risk, Therapy, Recurrence, Colon, Extrapyramidal system, Population, CET, EBMT, Hematopoietic stem cell transplantation, Graft-versus-host disease, Chicago (franchise), Death, Growth, Adult, David Berry (inventor), Mouse, Bloodstream infections, HSCT, SEC, Doctor of Philosophy, Program, Ulcerative colitis, U.S. Securities and Exchange Commission, Tissue, Immunodeficiency, Security (finance), Safety, Clinical and Translational Science, Annual general meeting, Inflammation, Vancomycin, Nasdaq, COVID-19, Trial of the century, Gastrointestinal tract, Infection, Annual report, FDA, University, Patient, Vaccine, Pharmaceutical industry, Serica, SER-155, Seres Therapeutics, SER-155, SERES THERAPEUTICS

Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut.

Key Points: 
  • Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut.
  • In cultured human cells designed to mimic the lining of the intestines, SER-155 protected the barrier between the colon and invading pathogens from inflammatory damage.
  • Together, these platforms allow the researchers to pinpoint the potential immunomodulatory effects of gut microbes introduced by SER-155.
  • The SER-109 program is being advanced to reduce the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

Retrieved on: 
Mardi, mars 15, 2022
Podiatry, Doctor of Philosophy, Time, Immunity, Pseudomonas aeruginosa, Meropenem, Global health, Staphylococcus aureus, OLC, Annual general meeting, Ohio State University, Vancomycin, CME, American Academy, Infection, Spine, AAOS, Foot, Research, Academy, Ankle, Biofilm, Trauma, Tobramycin, Genetically modified bacteria, Rifampicin, Surgeon, Pharmaceutical industry, Orthopedic surgery

The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm.

Key Points: 
  • The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm.
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "Biocomposites is excited to present new STIMULAN data at this distinguished annual meeting as part of our ongoing commitment to share insights and deliver innovative products that help surgeons with their infection management."
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.
  • Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world.

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

Retrieved on: 
Mardi, mars 15, 2022
Podiatry, Doctor of Philosophy, Time, Immunity, Pseudomonas aeruginosa, Meropenem, Global health, Staphylococcus aureus, OLC, Annual general meeting, Ohio State University, Vancomycin, CME, American Academy, Infection, Spine, AAOS, Foot, Research, Academy, Ankle, Biofilm, Trauma, Tobramycin, Genetically modified bacteria, Rifampicin, Surgeon, Pharmaceutical industry, Antibiotics, Orthopedic surgery, EU

KEELE, England, March 15, 2022 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce that Professor Paul Stoodley will be presenting the results of his in vitro study into the effectiveness of different dual combination antibiotics in killing antibiotic resistant and tolerant persister cells in lawn biofilms of Staphylococcus aureus and Pseudomonas aeruginosa at the American Academy of Orthopaedic Surgeons Annual Meeting (AAOS), being held in Chicago, 22-26 March 2022.

Key Points: 
  • The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm.
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "Biocomposites is excited to present new STIMULAN data at this distinguished annual meeting as part of our ongoing commitment to share insights and deliver innovative products that help surgeons with their infection management."
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.
  • Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world.

PDI HEALTHCARE INTRODUCES NOVEL DISINFECTANTS TO BETTER PROTECT HEALTHCARE ENVIRONMENTS DURING CRITICAL TIME

Retrieved on: 
Mardi, mars 8, 2022
Risk, Subclinical infection, Infection, Infectious Diseases Society of America, ESKAPE, Patient, Klebsiella pneumoniae, Staphylococcus aureus, Hospital, Research, PDI, HAI, Korea Disease Control and Prevention Agency, Norovirus, Methicillin, Clostridioides difficile (bacteria), The New England Journal of Medicine, Enterobacteriaceae, Solution, Multistable perception, Disinfectant, Acinetobacter baumannii, COVID-19, Candida auris, Vancomycin, Klebsiella aerogenes, New Delhi metallo-beta-lactamase 1, Clostridioides, Environment, Enterobacter, Hydrogen peroxide, CDC, MDR, VRE, EPA, Health, Center, Severe acute respiratory syndrome coronavirus 2, CAD, Pseudomonas aeruginosa, No, MRSA, Pharmaceutical industry, Sewage, Eyeish

"Given PDI's long legacy of pioneering important infection prevention solutions, we are proud to offer healthcare facilities a solution that protects surfaces and equipment from recontamination around the clock."

Key Points: 
  • "Given PDI's long legacy of pioneering important infection prevention solutions, we are proud to offer healthcare facilities a solution that protects surfaces and equipment from recontamination around the clock."
  • "Today's vulnerable healthcare environment has prompted an urgent need to strengthen infection prevention programs to better safeguard patients and staff," said Watts.
  • "Multiple layers of defense, including effective and easy-to-use disinfectants, will continue to be key to helping prevent infections, save costs, and improve care."
  • PDI has three divisions, PDI Healthcare, Sani Professional and PDI Contract Manufacturing.

Osteal Therapeutics Closes an Oversubscribed $30 Million Series B Financing to Advance Platform Therapy for Treatment of Musculoskeletal Infection

Retrieved on: 
Mardi, mars 8, 2022
Hip, Infection, Patient, Vancomycin, Randomized controlled trial, Population, Knee, Quality of life, Biofilm, Safety, Director, Principal, FDA, Therapy, Board, HCL, HM Capital Partners, Venture round, APEX, Tobramycin, GLOBE, Pharmaceutical industry, DALLAS

DALLAS, March 08, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the completion of an oversubscribed $30 million Series B equity financing. The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.

Key Points: 
  • DALLAS, March 08, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (Osteal), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the completion of an oversubscribed $30 million Series B equity financing.
  • HM Capital led the round with full participation by existing investors Johnson and Johnson Development Corporation (JJDC) and Medvest Capital.
  • The Series B funding will be used primarily to advance Osteals lead program, VT-X7 for periprosthetic joint infection (PJI), into later-stage clinical trials.
  • Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

Retrieved on: 
Lundi, mars 7, 2022
Capsule, Exotoxin, CDI, Clostridioides difficile (bacteria), DRSP, The New England Journal of Medicine, Inflammation, Clostridioides, Extrapyramidal system, Firmicutes, Kepler-86, Private Securities Litigation Reform Act, Enterococcus, Vancomycin, Wall, Germination, Metabolism, Company, Incidence, IDSA, Risk, Pharmacokinetics, Infection, IIIC, QIDP, Virulence, Marketing, Maintenance, Gram-positive bacteria, Epithelium, Methicillin-resistant Staphylococcus aureus, Liver, VRE, NASDAQ, Clinical, Gram, Recurrence, Patient, GUH, Hospital, Death, Actinobacteria, Microorganism, GI, DNA, Safety, Lessa, Structural Classification of Proteins database, Diarrhea, Mortality, MRSA, Pharmaceutical industry, Dietary supplement

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Key Points: 
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
    About the Ibezapolstat Phase 2 Clinical Trial.
  • In this cohort, 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Global Hospital Infection Therapeutics Market Report 2021: Market Reached a Value of Approx $11 Billion in 2020 - Trends, Share, Size, Growth, Opportunities and Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Lundi, janvier 24, 2022
Hospitals, Pharmaceutical, Health, Research, Cell wall, Urinary tract infection, Tigecycline, Cephalosporin, Vaccine, Vancomycin, R, Nursing, Linezolid, COVID-19, Hospital-acquired pneumonia, Caspofungin, Industry, Infection, Hospital, Carbapenem, Subclinical infection, Therapy, Degenerative disease, Hospital-acquired infection, Bloodstream infections, Aminoglycoside, Antibiotics, Pharmaceutical industry, Fine chemical, Sex industry, Growth

The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global hospital infection therapeutics market reached a value of around US$ 11 Billion in 2020.
  • How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
  • What is the structure of the global hospital infection therapeutics market and who are the key players?

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

Retrieved on: 
Lundi, janvier 10, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Aureus, Clinical trial, Vancomycin, Randomness, MRSA, SEC, Safety, Trial of the century, Nervous system, Single, US, JT Group Limited, Staphylococcus, Bacteria, Volunteering, Infection, Pharmacokinetics, Technology, Patient, World Health Organization, Brain, Neuroblastoma, Research, Adult, IND, ECG, Female, World, Methicillin, MAD, Staphylococcus aureus, Male, SAD, Lists of diseases, Euronext Paris, Vital signs, Prospectus, Therapy, Mortality, MYCN, Pharmaceutical industry, Science, EU, ALS-4, SACT-1, Aptorum Group Limited, ALS-4, SACT-1, APTORUM GROUP LIMITED

The safety data of the last SAD cohort (300mg) and MAD cohort (200mg twice a day for 14 days) are pending.

Key Points: 
  • The safety data of the last SAD cohort (300mg) and MAD cohort (200mg twice a day for 14 days) are pending.
  • SACT-1s first in-human clinical trial is a Phase 1, Open-label Randomized, Single Cross Over Bioavailability and Food Effect Study of SACT-1 in healthy adult volunteers.
  • Aptorum is pleased to announce the successful completion of the trial, during which no SAE were observed.
  • This milestone supports the focus of Aptorum Group to embark on the exciting Phase II clinical trials for ALS-4 and planned Phase Ib/2a clinical trials for SACT-1, subject to IND clearance.